Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro

https://doi.org/10.1016/0014-2999(94)90394-8Get rights and content

Abstract

Proliferation of smooth muscle cells within the intima plays a key role in vascular occlusive disorders such as atherosclerosis and restenosis following balloon angioplasty. Among the factors that may be important in the development of vascular lesions, several authors have reported that the local angiotensin system participates in modulating the proliferation of smooth muscle cells after arterial injury. This study was therefore designed to characterize the antagonistic properties and to investigate the antiproliferative effect of a newly developed non-peptide angiotensin II AT1 receptor antagonist, SR 47436. This compound is a potent and competitive antagonist of the binding of [125I]angiotensin II to its receptor on cultured human aortic smooth muscle cells, exhibiting an IC50 value of 1.7 ± 0.6 nM. SR 47436 was 10-fold more potent than DuP 753 (Losartan) (IC50 = 20.8 ± 3.7 nM). In these same cells, SR 47436 potently inhibited the angiotensin II-induced [Ca2+]i increase (IC50 = 0.53 ± 0.13 vs. 7.4 ± 1.3 nM for DuP 753). Angiotensin II is a potent mitogen for human aortic smooth muscle cells in culture, exhibiting a maximum proliferative response at 1 μM. SR 47436 and Losartan prevented angiotensin II-induced proliferation of these cells in a dose-dependent manner (IC50 = 0.32 ± 0.09 and 0.71 ± 0.8 μM, respectively). SR 47436 displayed a marked in vitro inhibition of serum-induced smooth muscle cell proliferation (IC50 = 5.5 ± 0.8 μM). A selective AT2 receptor antagonist, PD 123177 did not affect angiotensin II-induced responses in these cells. This in vitro study shows that SR 47436 is a potent inhibitor of angiotensin II-induced smooth muscle cell growth and thus may have beneficial effects in the development and regression of vascular hypertrophy, which is associated with the development of atherosclerosis, restenosis and hypertension.

References (43)

  • B. Teutsch et al.

    A recombinant rat vascular AT1 receptor confers growth properties to angiotensin II in chinese hamster ovary cells

    Biochem. Biophys. Res. Commun.

    (1992)
  • S. Whitebread et al.

    Preliminary biochemical characterization of two angiotensin II receptor subtypes

    Biochem. Biophys. Res. Commun.

    (1989)
  • H. Azuma et al.

    Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, Losartan

    Br. J. Pharmacol.

    (1992)
  • M. Burnier et al.

    In vitro effect of DuP 753, a nonpeptide angiotensin II receptor antagonist, on human platelets and rat vascular smooth muscle cells

    Am. J. Hyper.

    (1991)
  • L. Capron et al.

    Effect of ramipril, an inhibitor of angiotensin converting enzyme, on the response of rat thoracic aorta to injury with a balloon catheter

    J. Cardiovasc. Pharmacol.

    (1991)
  • C. Cazaubon et al.

    Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist

    J. Pharmacol. Exp. Ther.

    (1993)
  • Y.C. Cheng et al.

    Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction

    Biochem. Pharmacol.

    (1973)
  • A.T. Chiu et al.

    Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent

    J. Pharmacol. Exp. Ther.

    (1990)
  • M.J. Daemen et al.

    Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall

    Circ. Res.

    (1991)
  • V.J. Dzau

    Vascular renin-angiotensin: a possible autocrine or paracrine system in control of vascular function

    J. Cardiovasc. Pharmacol.

    (1984)
  • N. Emmet et al.

    The inhibition of cultured smooth muscle cell growth by saralasin

  • Cited by (51)

    • Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease

      2016, Pharmacology and Therapeutics
      Citation Excerpt :

      With this caveat in mind inhibition of ANG-induced hypertrophy and/or proliferation has been shown in cultured VSMCs from multiple species including rats (Ko et al., 1992; Millet et al., 1992; Sachinidis et al., 1992, 1993; Koh et al., 1994; Sung et al., 1994; Flesch et al., 1995; Itazaki et al., 1995; Kubo et al., 1996; Sachinidis et al., 1996a, 1996b; Graf et al., 1997; Virone-Oddos et al., 1997; Fukuda et al., 1999; Muniz et al., 2001; Touyz et al., 2001b) and humans (Herbert et al., 1994; Mueck et al., 1999; Wang et al., 2012a). Its antagonism has been demonstrated with multiple ARBs including candesartan and its prodrug (Koh et al., 1994; Flesch et al., 1995; Itazaki et al., 1995; Kubo et al., 1996; Sachinidis et al., 1996a, 1996b; Fukuda et al., 1999), eprosartan (Sung et al., 1994), irbesartan (Herbert et al., 1994; Graf et al., 1997; Xi et al., 1999; Muniz et al., 2001; Touyz et al., 2001b), losartan and its active metabolite EXP3174 (Ko et al., 1992; Millet et al., 1992; Sachinidis et al., 1992, 1993; Herbert et al., 1994; Sung et al., 1994; Itazaki et al., 1995; Virone-Oddos et al., 1997), telmisartan (Wang et al., 2012a) and valsartan (Mueck et al., 1999; Wang et al., 2012a). However, a study in isolated rat aorta found that ANG stimulated protein but not DNA synthesis in a losartan-sensitive manner (Holycross et al., 1993), questioning whether the proliferation-enhancing effects observed with cultured VSMC also occur in situ.

    • Angiotensin II receptor type 1 (AT<inf>1</inf>) selective nonpeptidic antagonists - A perspective

      2010, Bioorganic and Medicinal Chemistry
      Citation Excerpt :

      Novel imidazole analogs connected to biphenyl moiety through nitrogen (e.g., 32) were reported to show weak potency.98 Bernhart et al. have reported SR 47436 (Irbesartan)99 (33), a potent AT1 selective (IC50 1.3 nM, rat liver) antagonist which antagonized the pressor response to Ang II in a dose-dependent manner (0.1–3 mg/kg, iv and 0.3–30 mg/kg, po).100,101 Compound 33 was found to be 10-fold more potent than losartan (IC50 20.8 nM).

    View all citing articles on Scopus
    View full text